Mankind Pharma, Innovent Biologics partner to commercialise Sintilimab

27 Dec 2024 Evaluate

Mankind Pharma and Innovent Biologics have partnered to exclusively license and commercialise innovative immunotherapy drug Sintilimab, used in the treatment of cancer, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.

Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.


Mankind Pharma Share Price

2278.70 2.15 (0.09%)
05-Mar-2025 14:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1576.00
Dr. Reddys Lab 1125.50
Cipla 1417.50
Lupin 2012.85
Zydus Lifesciences 886.35
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...